TD Cowen analyst Yaron Werber has reiterated their bullish stance on FHTX stock, giving a Buy rating on October 31.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Yaron Werber has given his Buy rating due to a combination of factors that highlight Foghorn Therapeutics’ promising pipeline and strategic collaborations. The company’s lead candidate, FHD-909, is advancing in a Phase 1a trial targeting SMARCA4-mutated cancers, with a decision on advancing to Phase 1b expected in the first half of 2026. This decision is anticipated to be a significant catalyst for the company, as the initial data from Phase 1a will provide insight into the drug’s potential efficacy.
Additionally, Foghorn’s preclinical pipeline is progressing well, with the CBP degrader expected to be IND-ready in 2026 and the EP300 degrader moving towards IND-enabling studies. The company also reported promising initial data for ARID1B, which could target a gene mutated in a significant percentage of solid tumors. Despite a recent management change, Foghorn’s financial position remains strong with a cash runway extending into 2028, supporting Werber’s positive outlook on the stock.
According to TipRanks, Werber is a 5-star analyst with an average return of 20.3% and a 60.42% success rate. Werber covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Roivant Sciences, and BioNTech SE.
In another report released on October 31, H.C. Wainwright also maintained a Buy rating on the stock with a $13.00 price target.